Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects

Chronic Low Back Pain Clinical Trial

Official title:

A Phase 1, Placebo-controlled, Randomized, Parallel Group Study to Evaluate the Tolerability, Safety and Pharmacokinetics of a Topical Patch AB001 Following Single and Repeated Administration in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03997734
• Other study ID #: ABS-102
• Status: Completed
• Phase: Phase 1
• Start date: June 24, 2019
• Est. completion date: November 11, 2019

Study information

• Verified date: March 2020
• Source: Frontier Biotechnologies Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study evaluates the safety, tolerability and pharmacokinetics of single and repeated doses of topical AB001 patch and the bioavailability relative to the oral capsule and topical positive comparative patch.

Description:

Eligible subjects will be randomly assigned to Treatment goup A, B and C.

In the experiment group A, 12 subjects with a ratio of 10:2 will receive one patch of AB001 or placebo batch on Day 1 of period 1, respectively, after a wash-out period of 14 days, 10 subjects received AB001 patch will be administered with an oral capsule of active ingredient on Day 20 of period 2.

In the experiment group B, 12 subjects with a ratio of 10:2 will receive two patches of AB001 or two placebo batches on Day 1 respectively, and then two patches daily from Day 8 to Day 20.

In the active comparator group C, 10 subjects will receive one patch of positive comparative patch on Day 1, and then once patch every two days from Day 8 to Day 20.

The tolerability, safety and pharmacokinetics of topical AB001 patch will be assessed in this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: November 11, 2019
• Est. primary completion date: November 11, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Healthy male and female subjects between 18 and 45 years with a BMI of 18 to 30 kg/m2, inclusive, and weigh at least 45 kg.

2. Subjects having normal skin without excessive hair growth on tested areas.

3. Evidence of a personally signed and dated informed consent document indicating that the subjects has been informed of all pertinent aspects of the trial.

4. Subjects who are willing to comply with scheduled visits and other trial procedures

Exclusion Criteria:

1. A history or presence of significant cardiovascular, neurological, hematological, psychiatric, infectious, hepatic, gastrointestinal, pulmonary, endocrine, immunologic or renal disease or other conditions known to interfere with the topical absorption, distribution, metabolism, or excretion of drugs or place the subjects at increased risk as determined by the investigator

2. History of hypersensitivity to NSAIDs

3. Clinically significant laboratory abnormalities as judged by the investigator

4. Known sensitivity to adhesive tape, component of the test products or topically applied products

5. Any active malignancy

6. Suffering from severe acne, moderate to severe hirsutism or androgenic alopecia

7. Any chronic skin disorder (e.g., eczema, psoriasis) likely to interfere with transdermal drug absorption or assessment of skin tolerability

8. Skin abnormalities likely to be aggravated by the study medication, such as dermatological diseases or infections, rash, skin sensitive to topical preparations or adhesive dressings

9. Pregnant and/or nursing women

10. Any visible skin disorder or abnormal skin pigmentation which, in the opinion of the investigator, would interfere with the outcome of the trial

11. History of alcohol or drug abuse within 18 months

12. Blood donation or significant blood loss within 60 days of dosing or plasma donation within 7 days of dosing

13. Use of any medication within 4 weeks prior to the first treatment or during the trial, which in the opinion of the investigator may influence the trial results or the safety of the subjects

14. Subjects who cannot avoid, throughout the duration of the trial, any swimming, any washing of the back, and sauna or any intense physical activity that might result in excessive sweating

15. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.

Related Conditions & MeSH terms

• Back Pain
• Chronic Low Back Pain
• Low Back Pain

Intervention

Drug:
• AB001
single and repeated dosing
• oral capsule
single dose
• positive comparative patch
single and repeated dosing
• Placebos
single and repeated dosing

Locations

Country	Name	City	State
China	The Third People's Hospital of Wuxi	Wuxi	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Frontier Biotechnologies Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with any adverse events (AEs)	An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.	From baseline through Day 26
Primary	Number of subjects any serious adverse events (SAEs)	An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect.	From baseline through Day 26
Secondary	Safety Assessments on Skin Reaction Evaluation	Topical Skin Reaction Score(0-2 is a better outcome): 0= no evidence of irritation; minimal erythema, barely perceptible; definite erythema, readily visible; minimal edema or minimal papular response; erythema and papules; definite edema; erythema, edema and papules; vesicular eruption; strong reaction spreading beyond application site	From baseline through Day 26
Secondary	pharmacokinetic parameters of AB001(Cmax)	Peak Plasma Concentration (Cmax)	Day 1 and Day 26
Secondary	pharmacokinetic parameters of AB001 (AUC)	Area under the plasma concentration versus time curve (AUC)	Day 1 and Day 26
Secondary	bioavailability of AB001	To determine the bioavailability of AB001	Day 1 and Day 26